Why Farbe Firma is the Top Manufacturer of Levetiracetam Injection
- Maulik Sudani
- 4d
- 7 min read
Last Updated: June 14, 2026
TL;DR: Levetiracetam Injection — a sterile, clear, colourless aqueous concentrate of levetiracetam, a broad-spectrum antiepileptic (anticonvulsant), supplied commonly as a 500 mg/5 mL single-dose vial (100 mg/mL) to be diluted before intravenous infusion — is the parenteral form clinicians use when a patient already established on, or needing to start, levetiracetam cannot take the oral route, as adjunctive therapy in partial-onset (focal) seizures, myoclonic seizures and primary generalised tonic-clonic seizures. Because the injection is a concentrate that must be diluted and infused, and because seizure control depends on an accurate, reproducible dose, each vial must deliver an exact, sterile, particulate-free amount at the labelled concentration, with the assay, the impurity and degradation profile, solution pH, fill volume, low particulate and endotoxin, a validated sterilisation route and verified container-closure integrity all mattering to safety and shelf life. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Levetiracetam Injection at our Gujarat, India facility and supplies it to hospital pharmacy, neurology, emergency and critical-care services, tenders, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Broad-spectrum antiepileptic (anticonvulsant) — Levetiracetam Injection is used as intravenous adjunctive therapy for partial-onset (focal) seizures, myoclonic seizures and primary generalised tonic-clonic seizures when the oral route is temporarily unavailable, providing a reliable parenteral alternative bioequivalent to the oral dose.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, dedicated solution compounding and vial filling lines, control of the stability-indicating assay, the impurity profile, solution pH, fill volume, particulate and endotoxin for a small-volume parenteral concentrate, with container-closure integrity verification on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, ICH Q1B photostability data, sterilisation and container-closure data, drug master files and CEP-style documentation for registrations including ministry-of-health, hospital-formulary and institutional tenders.
End-to-end CDMO services: Sterile-solution contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tamper-evident tender-ready vial packaging and import/export coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Levetiracetam Injection Demands a Premium Manufacturer
Levetiracetam Injection holds a dependable, increasingly central place in neurology, emergency medicine and critical care across every market. It is the intravenous broad-spectrum antiepileptic that clinicians reach for when a patient who needs levetiracetam cannot swallow or absorb the oral form — peri-operatively, during an acute illness, in the emergency department, or in the intensive-care unit — as adjunctive therapy in partial-onset (focal) seizures, in myoclonic seizures of juvenile myoclonic epilepsy, and in primary generalised tonic-clonic seizures. Presented as a concentrate that is diluted into a compatible infusion fluid and given over a short intravenous infusion, the injection lets the prescriber continue seizure control without interruption, at a dose bioequivalent to the patient's oral regimen. In each of these settings the dose delivered from each vial must be exact, sterile, particulate-free and reliably the same from unit to unit, because consistent seizure control depends on a precise, reproducible dose.
That clinical reality places real demands on the manufacturer. The product is presented as a low-volume aqueous concentrate that must stay a clear, colourless solution within a defined pH window throughout shelf life and must remain compatible with the common diluents into which it is mixed. The assay of levetiracetam must be exact; the impurity and degradation profile must stay within tight limits; the pH and the deliverable volume must be controlled tightly so each vial gives the labelled dose at the labelled concentration; the solution must be free of visible and sub-visible particulates and low in endotoxin; and it must be sealed in a vial whose container-closure integrity holds across shelf life. Choosing a Levetiracetam Injection manufacturer that treats the stability-indicating assay, pH and fill-volume control, the validated sterilisation route, particulate and endotoxin control and container-closure integrity as core engineering disciplines is what protects the patient at the point of care.
What Sets a World-Class Levetiracetam Injection Manufacturer Apart
A world-class manufacturer of Levetiracetam Injection invests in three areas that weaker suppliers underfund: a precise, stability-indicating assay of levetiracetam with the tight related-substance and degradation-product control by HPLC that a parenteral antiepileptic demands, a robust, validated aseptic solution-fill process — with terminal moist-heat sterilisation where the formulation and container permit it, otherwise sterile filtration and aseptic filling — that protects the assay, the pH and the clarity of the solution, and tender-ready dossier support for a hospital-formulary neurology product procured through pharmacy and ministry-of-health channels. It starts with the active — pharmacopoeial-grade levetiracetam sourced from qualified, audited API makers, with full assay, related-substance and impurity profiling and certificates of analysis verified by the receiving laboratory before the material enters production.
Compounding and filling then have to defend both the assay and the dose. The bulk solution is compounded in water-for-injection at the controlled pH that keeps levetiracetam stable and fully in solution, sterile-filtered through 0.22 µm membrane, and filled into vials under ISO Class 5 conditions, with the validated sterilisation route — terminal moist-heat where qualified, otherwise full aseptic processing — locked in the master batch record. Filled vials are 100 % inspected for fill, seal, clarity and particulate defects; in-process and release testing confirm the assay of levetiracetam by validated HPLC, the related-substance profile, solution pH, deliverable volume, visible and sub-visible particulate matter, and endotoxin is held well within limits so the concentrate is safe to dilute and infuse intravenously. Because the product is a concentrate diluted at the bedside, dilution compatibility and in-use stability are confirmed and documented for the prescriber.
Quality Systems Behind Every Levetiracetam Injection
Every Farbe Firma Levetiracetam Injection batch is released only after a full stack of quality checks: stability-indicating HPLC assay of levetiracetam against pharmacopoeial reference standards, control of related substances and degradation products by HPLC, solution pH, deliverable (fill) volume, clarity and colour of the solution, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, and container-closure integrity for the vial format. Certificates of analysis are issued with full traceability back to each API lot, the primary-packaging lot and the qualified person responsible for release.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, validated sterilisation and depyrogenation equipment, validated vial-filling lines with 100 % inspection, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Because levetiracetam is given to maintain seizure control and the assay, pH, clarity and particulate burden of the concentrate drive both efficacy and safety, we treat the stability-indicating HPLC assay, the solution pH, the deliverable volume and the related-substance profile as critical quality attributes and trend them across batches, not merely as one-off release tests. Stability is tracked under both long-term (25 °C / 60 % RH) and accelerated (40 °C / 75 % RH) ICH Q1A conditions, with ICH Q1B photostability challenge, and in-use dilution stability is established to support bedside preparation.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Levetiracetam Injection manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables, including a broad small-volume parenteral portfolio across neurology, critical-care, anti-infective and supportive-care categories. For Levetiracetam Injection specifically, we supply the 500 mg/5 mL (100 mg/mL) single-dose vial of sterile concentrate under WHO-GMP conditions, with country-specific strengths, fill configurations, tamper-evident packs and pack counts available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier — including the stability-indicating-assay, pH, sterilisation and container-closure data package — ready to hand for registration and tender qualification.
Our CDMO services scale cleanly from single-hospital supply to full national tender procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, assay and related-substances method-validation data, sterilisation and container-closure reports, translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics to the destination market. When a buyer needs Levetiracetam Injection at tender scale our regulatory, manufacturing and logistics teams move as one: dossier, validation reports, artwork, line slot and shipment plan delivered as a single coordinated package.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor and into the compounding and filling suites; our quality unit answers technical queries with primary data, not slogans; and our reviewer team — practising pharmacists and R&D scientists — can talk through API sourcing, stability-indicating assay development, related-substance and degradation control, pH and solubility design, the choice between terminal sterilisation and aseptic filling, fill-volume and deliverable-dose control, dilution-compatibility and in-use stability, particulate and endotoxin control, container-closure integrity and shelf-life choices in real detail. For a parenteral antiepileptic where assay accuracy, pH and particulate control directly govern both seizure control and safety, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Levetiracetam Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Levetiracetam Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, dedicated solution compounding and vial filling lines, validated sterilisation, qualified water-for-injection systems, 100 % inspection and continuous environmental monitoring.
Which strengths and pack sizes of Levetiracetam Injection do you supply?
Our standard presentation is the 500 mg/5 mL (100 mg/mL) single-dose vial of sterile levetiracetam concentrate, to be diluted before intravenous infusion. Custom strengths, fill configurations, vial or ampoule formats, tamper-evident counts per pack and country-specific artwork are available under contract manufacturing agreements.
What is Levetiracetam Injection mainly used for?
Levetiracetam Injection is used as intravenous adjunctive therapy for partial-onset (focal) seizures, myoclonic seizures and primary generalised tonic-clonic seizures when the oral route is temporarily unavailable. It is a concentrate that must be diluted before infusion; Farbe Firma verifies the assay, clarity, deliverable volume, pH and particulate matter at release and documents dilution compatibility for the prescriber.
Can Farbe Firma support country-specific registrations for Levetiracetam Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, assay and related-substances method-validation data, sterilisation and container-closure reports, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. We support registrations and tender qualification in 30+ countries across Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
What is the minimum order quantity for Levetiracetam Injection contract manufacturing?
MOQs vary by strength, vial size, sterilisation route, label complexity and dossier requirements. For our small-volume parenteral presentations we accommodate hospital-scale and full national-tender-scale orders. Contact director@farbefirma.org for a specific quotation.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments